California Gov. Jerry Brown should veto a state law that would limit the use of biosimilars because it is more about protecting profits rather than patients, according to this editorial. The state should not rush to pass SB 598 and wait for the FDA to do its work as standards for safely substituting biosimilars could be laid out early in 2014.

Related Summaries